Saptalis Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SAPTALIS PHARMS, and when can generic versions of SAPTALIS PHARMS drugs launch?
SAPTALIS PHARMS has twenty-two approved drugs.
There is one US patent protecting SAPTALIS PHARMS drugs.
There are five patent family members on SAPTALIS PHARMS drugs in five countries and seventy-nine supplementary protection certificates in fifteen countries.
Summary for Saptalis Pharms
| International Patents: | 5 |
| US Patents: | 1 |
| Tradenames: | 20 |
| Ingredients: | 20 |
| NDAs: | 22 |
Drugs and US Patents for Saptalis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saptalis Pharms | FLUOCINOLONE ACETONIDE | fluocinolone acetonide | OIL/DROPS;OTIC | 202705-001 | Sep 9, 2016 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Saptalis Pharms | CYCLOPENTOLATE HYDROCHLORIDE | cyclopentolate hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 205937-001 | Dec 9, 2015 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Saptalis Pharms | DESOXIMETASONE | desoximetasone | CREAM;TOPICAL | 203234-001 | Jun 12, 2015 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Saptalis Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3768321 | ⤷ Try a Trial |
| Canada | 3087789 | ⤷ Try a Trial |
| Brazil | 112020014376 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Saptalis Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1412357 | 122008000046 | Germany | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE SITAGLIPTINPHOSPHAT- MONOHYDRAT, IN KOMBINATION MIT METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 FIRST REGISTRATION: CH/LI 58450 01 58450 02 58450 03 20080408 |
| 1261586 | 1290013-0 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SAXAGLIPTIN/METFORMIN; REG. NO/DATE: EU/1/11/731/001 20111124 |
| 1718641 | 2012/008 | Ireland | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
